Skip to main content
Premium Trial:

Request an Annual Quote

SQI Diagnostics, Isis Ink Immunogenicity Assay Development Deal

NEW YORK (GenomeWeb News) – Toronto-based life sciences and diagnostics company SQI Diagnostics today announced a method development deal with Isis Pharmaceuticals.

The deal covers the development of a multiplexed assay using SQI's Ig Plex multiplexing immunogenicity technology. Financial and other terms of the agreement were not disclosed.

SQI said that using its Ig Plex tests in clinical studies provides drug development firms quantitative results for multiple anti-drug antibody isotypes in one test. It also provides the use of SQI's automated systems to improve the benefits of multiplexing during a drug development's immunogenicity testing phase, and enables the drug developer to get ahead of emerging regulatory guidelines covering immunogenicity testing.

"We believe that our multiplexing solutions and services are highly complementary with Isis' extensive portfolio of drugs under development," SQI CEO Andrew Morris said in a statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.